SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Elan Corporation, plc (ELN)
An SI Board Since October 1996
Posts SubjectMarks Bans Symbol
10345 171 0 ELN
Emcee:  Harold Engstrom Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
9645Much has been said and written about the new evaluation approach that WYE and ELArthur Radley-4/26/2008
9644Orla (ncb brokers) today pre conf call: ----------------------------------------fred hayes-4/24/2008
9643Based on current patient adds and rounding, you get: end of June 30 end of SeptRobohogs-4/23/2008
9642If this quote from (BIIB) management is true and with only $165M in revenue for Arthur Radley-4/23/2008
9641Tysabri sales rebounding nicely.....This from BIIB report this morning.. GlobalArthur Radley-4/23/2008
9640Thanks, Fred.tom pope-4/22/2008
9639Of course. Here's the stuff from Orla: -------------------------------------fred hayes-4/22/2008
9638Elan reports Thursday morning. Has anybody seen any revenue projections that apptom pope-4/22/2008
9637Wyeth, Elan Halt Alzheimer Drug Trial 04/17/08 - 01:01 PM EDT Wyeth (WYE - CraSlugger-4/18/2008
9636Study Evaluating ACC-001 in Mild to Moderate Alzheimers Disease Subjects This sQualified Opinion-4/17/2008
9635Orla again, following up 4.17.08: -------------------------------------- • Follofred hayes-4/17/2008
9634Haven't we all been on a roller-coaster. Have owned ELN for about two yearsRaptech-4/16/2008
9633I hope you're right. I've been on such a roller-coaster ride with this steve kammerer-4/16/2008
9632Your guess is as good as mine. Looks pretty comparable and has advantage of oralfred hayes-4/16/2008
9631How does the oral drug, mentioned a couple of posts ago for MS, affect mid termsteve kammerer-4/16/2008
9630Orla sez (4.16.08): ------------------------------ • BiogenIdec and Elan have prfred hayes-4/16/2008
9629Relaunched Drug Tysabri Avoids Prior Brain Problem By THOMAS GRYTA [WSJ] April 1sim1-4/16/2008
9628Over 25K people now on Tysabri. Jump of 25% q/q. Adoption seems to be acceleratirkrw-4/15/2008
9627FTY720, a novel oral therapy in development for MS, shows sustained benefits forQualified Opinion-4/15/2008
9626Novartis provides an encouraging update and set of longer term results on FTY720Biotech Jim-4/15/2008
9625DNA's Rituxan Flunks MS Trial Message 24500748tnsaf-4/15/2008
9624Just a small distinction--He is not a reporter. He takes a position. You can calewolf-4/13/2008
9623Thanks for that Rob. I actually am thankful for his analysis in this case - tolRobohogs-4/13/2008
9622Are you a cult leader ? <g> --------------------------------------------Qualified Opinion-4/12/2008
9621>>It could all be innocent. LOL Best laugh today. ijIRWIN JAMES FRANKEL-4/7/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News